Sol-Gel Technologies

Sol-Gel Technologies is an experienced dermatology company that leverages innovative approaches to develop advanced treatments for patients with severe skin conditions. Its pipeline includes SGT-610 (topically applied 2% patidegib gel) for Gorlin syndrome and high-frequency basal cell carcinoma, SGT-210 (topical erlotinib) for undisclosed indications, and the marketed products TWYNEO (tretinoin and benzoyl peroxide cream, 0.1%/3%) for acne vulgaris and EPSOLAY (benzoyl peroxide cream, 5%) for inflammatory lesions of rosacea. TWYNEO is described as the first and only FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide for acne vulgaris in adults and pediatric patients nine years of age and older, and is currently available in the US, with availability in Canada expected in early 2024.

Sol-Gel Technologies is an experienced dermatology company that leverages innovative approaches to develop advanced treatments for patients with severe skin conditions. The company identifies and develops promising dermatology assets, enhances their trajectory, and delivers innovative formulations to patients. Its pipeline spans research through FDA approval, including SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with Phase III started December 2023, and for high-frequency BCC, with Phase III starting 2027; SGT-210 (topical erlotinib) for undisclosed indications, which has completed Phase I; and the marketed products TWYNEO and EPSOLAY. TWYNEO is currently available in the US and will be available in Canada in early 2024.

An experienced dermatology company developing advanced treatments for patients with severe skin conditions, with a focus on rare skin conditions such as Gorlin syndrome and pachyonychia congenita.

• TWYNEO

  TWYNEO is a topical treatment for acne. It is the first and only FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide (BPO) for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older. TWYNEO is currently available in the US and will be available in Canada in early 2024.

• EPSOLAY

  EPSOLAY (benzoyl peroxide cream, 5%) is marketed for inflammatory lesions of rosacea.

• SGT-610

  SGT-610 is a topically applied 2% patidegib gel being developed for the prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome, and for high-frequency BCC. Phase III for Gorlin syndrome started December 2023; Phase III for high-frequency BCC starts 2027.

• SGT-210

  SGT-210 is a topical erlotinib for undisclosed indications; Phase I has been completed.

1. 1Sol-Gel Technologies | Harnessing Dermatological Innovationsol-gel.com
2. 2Pioneering Dermatological Advancements | About Sol-Gel Technologiessol-gel.com
3. 3Products With Breakthrough Formulations | Sol-Gel Technologiessol-gel.com
4. 4A Pipeline of Advanced Dermatological Drugs | Sol-Gel Technologiessol-gel.com
5. 5Sol-Gel Technologies (Israel)wikidata.org